264 related articles for article (PubMed ID: 29189181)
1. "Good Fashion is Evolution, Not Revolution" - Methods to Enhance Existing Anticancer Medicines, Primarily with the Use of Transition Metal.
Guzowska M; Kalinowska M; Lewandowski W
Anticancer Agents Med Chem; 2018; 18(4):476-487. PubMed ID: 29189181
[TBL] [Abstract][Full Text] [Related]
2. Computer-aided drug design and virtual screening of targeted combinatorial libraries of mixed-ligand transition metal complexes of 2-butanone thiosemicarbazone.
Khan T; Ahmad R; Azad I; Raza S; Joshi S; Khan AR
Comput Biol Chem; 2018 Aug; 75():178-195. PubMed ID: 29883916
[TBL] [Abstract][Full Text] [Related]
3. Homo and heteromultimetallic complexes containing a group 8 transition metal and μ-diphosphine bridging ligands involved in anticancer research: A review.
Roufosse B; Serbu C; Marschner C; Prince S; Blom B
Eur J Med Chem; 2024 Aug; 274():116528. PubMed ID: 38805938
[TBL] [Abstract][Full Text] [Related]
4. Metal N-heterocyclic carbene complexes as potential antitumor metallodrugs.
Liu W; Gust R
Chem Soc Rev; 2013 Jan; 42(2):755-73. PubMed ID: 23147001
[TBL] [Abstract][Full Text] [Related]
5. An Insight into the Effect of Schiff Base and their d and f Block Metal Complexes on Various Cancer Cell Lines as Anticancer Agents: A Review.
Presenjit ; Chaturvedi S; Singh A; Gautam D; Singh K; Mishra AK
Anticancer Agents Med Chem; 2024; 24(7):488-503. PubMed ID: 38279753
[TBL] [Abstract][Full Text] [Related]
6. Transition metal based anticancer drugs.
Garbutcheon-Singh KB; Grant MP; Harper BW; Krause-Heuer AM; Manohar M; Orkey N; Aldrich-Wright JR
Curr Top Med Chem; 2011; 11(5):521-42. PubMed ID: 21189131
[TBL] [Abstract][Full Text] [Related]
7. Multi-Targeted Anticancer Agents.
Zheng W; Zhao Y; Luo Q; Zhang Y; Wu K; Wang F
Curr Top Med Chem; 2017 Nov; 17(28):3084-3098. PubMed ID: 28685693
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in ruthenium and platinum based supramolecular coordination complexes for antitumor therapy.
Zhang X; Liu D; Lv F; Yu B; Shen Y; Cong H
Colloids Surf B Biointerfaces; 2019 Oct; 182():110373. PubMed ID: 31376689
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, crystal structures, molecular docking, and in vitro biological activities of transition metals with 4-(2,3-dichlorophenyl)piperazine-1-carboxylic acid.
Yang DD; Chen YN; Wu YS; Wang R; Chen ZJ; Qin J; Qian SS; Zhu HL
Bioorg Med Chem Lett; 2016 Jul; 26(14):3295-3299. PubMed ID: 27241690
[TBL] [Abstract][Full Text] [Related]
10. Ternary metal complexes of guaifenesin drug: Synthesis, spectroscopic characterization and in vitro anticancer activity of the metal complexes.
Mahmoud WH; Mahmoud NF; Mohamed GG; El-Sonbati AZ; El-Bindary AA
Spectrochim Acta A Mol Biomol Spectrosc; 2015; 150():451-60. PubMed ID: 26067934
[TBL] [Abstract][Full Text] [Related]
11. New bio-sensitive and biologically active single crystal of pyrimidine scaffold ligand and its gold and platinum complexes: DFT, antimicrobial, antioxidant, DNA interaction, molecular docking with DNA/BSA and anticancer studies.
Sankarganesh M; Dhaveethu Raja J; Sakthikumar K; Solomon RV; Rajesh J; Athimoolam S; Vijayakumar V
Bioorg Chem; 2018 Dec; 81():144-156. PubMed ID: 30121002
[TBL] [Abstract][Full Text] [Related]
12. Azaindoles: Suitable ligands of cytotoxic transition metal complexes.
Štarha P; Trávníček Z
J Inorg Biochem; 2019 Aug; 197():110695. PubMed ID: 31054487
[TBL] [Abstract][Full Text] [Related]
13. Alkaloid-metal based anticancer agents.
Chen ZF; Liu YC; Huang KB; Liang H
Curr Top Med Chem; 2013; 13(17):2104-15. PubMed ID: 23978139
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and characterization of the ligand based on benzoxazole and its transition metal complexes: DNA-binding and antitumor activity.
Jiang J; Tang X; Dou W; Zhang H; Liu W; Wang C; Zheng J
J Inorg Biochem; 2010 May; 104(5):583-91. PubMed ID: 20202687
[TBL] [Abstract][Full Text] [Related]
15. Recent development of transition metal complexes with in vivo antitumor activity.
Liang JX; Zhong HJ; Yang G; Vellaisamy K; Ma DL; Leung CH
J Inorg Biochem; 2017 Dec; 177():276-286. PubMed ID: 28641893
[TBL] [Abstract][Full Text] [Related]
16. Fluorinated-NHC Transition Metal Complexes: Leading Characters as Potential Anticancer Metallodrugs.
Rufino-Felipe E; Colorado-Peralta R; Reyes-Márquez V; Valdés H; Morales-Morales D
Anticancer Agents Med Chem; 2021; 21(8):938-948. PubMed ID: 32900353
[TBL] [Abstract][Full Text] [Related]
17. A Cancer Cell-Selective and Low-Toxic Bifunctional Heterodinuclear Pt(IV)-Ru(II) Anticancer Prodrug.
Ma L; Lin X; Li C; Xu Z; Chan CY; Tse MK; Shi P; Zhu G
Inorg Chem; 2018 Mar; 57(5):2917-2924. PubMed ID: 29436828
[TBL] [Abstract][Full Text] [Related]
18. Alkyl chain-modified cyclometalated iridium complexes as tunable anticancer and imaging agents.
Laha P; De U; Chandra F; Dehury N; Khullar S; Kim HS; Patra S
Dalton Trans; 2018 Nov; 47(44):15873-15881. PubMed ID: 30358775
[TBL] [Abstract][Full Text] [Related]
19. Progresses in TCM metal-based antitumour agents.
Chen ZF; Liang H
Anticancer Agents Med Chem; 2010 Jun; 10(5):412-23. PubMed ID: 20545619
[TBL] [Abstract][Full Text] [Related]
20. A survey of the mechanisms of action of anticancer transition metal complexes.
Marloye M; Berger G; Gelbcke M; Dufrasne F
Future Med Chem; 2016 Dec; 8(18):2263-2286. PubMed ID: 27874280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
